Shanghai, China — Recently, MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) has received marketing approval for its second-generation balloon catheter , Alwide^® Plus Balloon Catheter (hereinafter referred to as "Alwide^® Plus") from Russian State Food and Drug Administration(RZN).

As an upgraded product of Alwide^® balloon catheter, Alwide^® Plus was approved by the China National Drug Administration (NMPA) on July 29, 2021, and its excellent performance has been widely recognized by the surgeons after its launch: Its ultra-low compliance can realize more precise balloon expansion to avoid vascular damage; high burst pressure performance can effectively expand the site of severe calcification, which can better cope with the characteristics of Chinese patients with high calcification; fast filling and pumping performance can minimize the impact of prolonged blood flow blockage on cardiac function, reduce the pacing time, and lower the risk of surgery; significantly improved anti-puncture performance can further increase the safety of balloon dilatation while bringing the surgeons a better experience.

The approval of Alwide^® Plus in Russia will help local TAVI physicians to cope with more challenges in different types of surgeries. At the same time, MicroPort^® CardioFlow’s self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System has also made progress in its registration in Russia, steadily moving forward on the path of international development.

In the future, MicroPort^® CardioFlow will develop more innovative products with international competitiveness, and provide high-quality, universal total solutions for structural heart disease to more patients around the world.

Notes:

[1] MicroPort^® CardioFlow Laboratory Test Data (compared with Alwide^® balloon catheter)